Common Dosage
5mg - 10mg weekly
Category
Mitochondrial
- Metabolic regulation
- Insulin sensitivity
- Physical performance
MOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA-c) was discovered in 2015 by Changhan David Lee and colleagues at USC as a small peptide encoded within the mitochondrial 12S ribosomal RNA gene — a peptide from a part of the genome not traditionally thought to encode proteins. This discovery was considered a paradigm shift in mitochondrial biology. MOTS-C circulates in the blood, declines with age, and appears to function as a mitochondrial signal peptide coordinating whole-body metabolic adaptation, particularly in response to exercise stress.
MOTS-C translocates from the mitochondria to the nucleus during metabolic stress, where it activates the AMPK pathway and modulates gene expression related to glucose metabolism, insulin sensitivity, and fatty acid oxidation. It also regulates the folate cycle and AICAR production — a natural AMPK activator. The net effect is improved metabolic flexibility and insulin sensitivity, mimicking many benefits of aerobic exercise.
- Insulin resistance and type 2 diabetes research
- Exercise mimicry and metabolic flexibility enhancement
- Aging-related metabolic decline
- Physical performance and endurance enhancement
- Obesity and fat metabolism
- Longevity research — levels correlate with healthy aging outcomes
Exercise Performance in Mice
MOTS-C administration in aged mice dramatically improved physical performance — with some experiments showing aged mice matching the performance of young mice — attributed to improved mitochondrial efficiency and metabolic substrate utilization in skeletal muscle.
Insulin Sensitivity
High-fat diet-induced insulin resistant mice showed rapid improvement in glucose tolerance and insulin sensitivity following MOTS-C treatment, with effects comparable to metformin in some parameters — but through a distinct mitochondrial signaling mechanism.
Human Centenarian Correlations
Epidemiological research found that Japanese centenarians had elevated circulating MOTS-C compared to elderly non-centenarians, suggesting a role for this peptide in exceptional longevity phenotypes — though causation vs. correlation is not established.
- Injection site pain is consistently reported as significant — warming the solution before injection is commonly recommended
- Human clinical trials are limited — most mechanistic data from rodent studies
- Optimal dosing frequency and long-term effects are not established in humans
- AMPK activation has broad metabolic effects — interactions with medications (particularly diabetes drugs) warrant consideration
- Storage requirements are strict — MOTS-C is relatively fragile compared to some other peptides
- Injection site pain (common)